News
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
FEATURED STORIES
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace.
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
The NDA acceptance is based on positive results from the KRYSTAL-1 trial, which looked into the effect of using 600mg BID of adagrasib in patients.
Psychedelics therapies – serotonin 2 A receptor agonists – are trying to enter mainstream medicine for depression and as anti-inflammatory or neuroprotective treatments.
TenSixteen Bio recently came out of stealth mode with $40 million in funding to target somatic mosaicism – particularly clonal hematopoiesis of indeterminate potential (CHIP).
As the market seems to be taking a turn against biotech stock, more companies are opting for private funding instead of going public for the moment. And VC firms are happy to jump in.
Together, Intellia and ONK hope to develop, engineer and test new allogeneic CRISPR-edited NK cell therapies.
After a filibuster was broken Monday, the Senate confirmed Califf’s nomination in a 50-46 bipartisan vote.
Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.
While the “speed of science” to develop a successful coronavirus vaccine against the novel COVID-19 has been record-setting, scientists are telling us it’s not enough.
After announcing that the FDA was investigating a possible death associated with its lymphoma drug Ukoniq (umbralisib), things are seemingly looking up for TG Therapeutics.